NEW YORK (GenomeWeb News) – Myriad Genetics today said that its Myriad RBM subsidiary has formed a research collaboration with DaVita Labs to discover protein-based biomarkers that could be used to benefit dialysis patients.

The firms said that the primary focus of the collaboration will be on markers that predict vascular access failure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.